Corbus Pharmaceuticals Holdings, Inc. (CRBP)
1.2300 +0.01 (0.82%)
After hours: 1:35PM EST
Chart Events
Performance Outlook
| Previous Close | 1.2000 |
| Open | 1.2200 |
| Bid | 1.2200 x 3200 |
| Ask | 1.2300 x 2900 |
| Day's Range | 1.1800 - 1.2200 |
| 52 Week Range | 0.9100 - 9.7800 |
| Volume | 2,029,090 |
| Avg. Volume | 5,619,487 |
| Market Cap | 102.525M |
| Beta (5Y Monthly) | 2.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7840 |
| Earnings Date | Nov 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.90 |
- Benzinga
ROCE Insights For Corbus Pharmaceuticals
During Q3, Corbus Pharmaceuticals (NASDAQ: CRBP) brought in sales totaling $1.23 million. However, earnings decreased 10.92%, resulting in a loss of $33.97 million. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss.What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, Corbus Pharmaceuticals posted an ROCE of -1.16%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on CRBPROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Corbus Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.For Corbus Pharmaceuticals, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.Q3 Earnings Recap Corbus Pharmaceuticals reported Q3 earnings per share at $-0.43/share, which did not meet analyst predictions of $-0.42/share.See more from Benzinga * Click here for options trades from Benzinga * Corbus Pharmaceuticals: Q3 Earnings Insights * Earnings Scheduled For November 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
* Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 12:35 PM EST.A live audio webcast of the presentation will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com. The webcast replay will be available approximately two hours after the event and will be archived for 90 days.About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here.For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook.Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.Corbus Pharmaceuticals Contacts: Ted Jenkins, Senior Director, Investor Relations and Corporate Communications Phone: +1 (617) 415-7745 Email: ir@corbuspharma.comLindsey Smith, Director, Investor Relations and Corporate Communications Phone: +1 (617) 415-7749 Email: mediainfo@corbuspharma.com
- SmarterAnalyst
Corbus Pharma Drops 6% On 3Q Miss; Street Sees 79% Upside
Shares of Corbus Pharmaceuticals are down about 5.7% in pre-market trading on Wednesday after reporting lower-than-expected 3Q results. The pharma giant posted a loss of $0.43 per share, which was larger than the loss of $0.41 per share expected by analysts and compared to the year-ago loss of $0.32.3Q revenues of $1.23 million also missed the consensus estimates of $3.24 million and declined 52.5% year-over-year, due to “revenue recognized under the Cystic Fibrosis Program Related Investment Agreement,” the company said.Corbus’ (CRBP) operating expenses increased by 27.2% year-over-year to $35.2 million in 3Q, primarily due to increased clinical trial costs. The company’s CEO Yuval Cohen said, “Our restructuring significantly improved our cash runway, so we can continue to work toward delivering a much-needed novel therapeutic option for patients while also giving us the resources to look at external assets that will be synergistic to our in-house capabilities.”Cohen also added that “We expect our cash runway to be further extended with the cost savings from our plan to shorten the DETERMINE Phase 3 dermatomyositis study to 28 weeks from one year. This decision is driven by recent changes in the dermatomyositis competitive landscape and will accelerate topline data readout to the second quarter of 2021.” (See CRBP stock analysis on TipRanks).Following the 3Q results, Oppenheimer analyst Leland Gershell maintained his Hold rating on the stock. Gershell said that “the recently announced corporate restructuring should extend cash runway to mid-2022.” Meanwhile, he also sees “balanced risk/reward heading into DM [dermatomyositis] top-line readout, which may come by 2Q21.”Currently, the Street supports Gershell’s outlook and assigns a Hold analyst consensus. The average price target stands at $2.18 implying upside potential of about 78.7% to current levels. Shares have declined by about 77.7% year-to-date.Related News: Amgen, AstraZeneca Deliver Successful Late-Stage Severe Asthma Trial Pfizer, BioNTech Announce COVID-19 Vaccine is 90% Effective Eli Lilly’s Covid-19 Antibody Treatment Gets FDA Emergency Use Nod More recent articles from Smarter Analyst: * Postal Realty's 3Q Sales More Than Double; BMO Sees 22% Upside * Advance Auto Parts' 3Q Profit Jumps 34%; Analyst Sticks To Hold * GameStop To Redeem $125M In Notes Early; Street Sees 38% Downside * Ulta Beauty Rises 7% On Plans To Enter Target Stores
